Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

CA Dinarello, A Simon… - Nature reviews Drug …, 2012 - nature.com
CA Dinarello, A Simon, JWM Van Der Meer
Nature reviews Drug discovery, 2012nature.com
Abstract Interleukin-1 (IL-1) is a highly active pro-inflammatory cytokine that lowers pain
thresholds and damages tissues. Monotherapy blocking IL-1 activity in autoinflammatory
syndromes results in a rapid and sustained reduction in disease severity, including reversal
of inflammation-mediated loss of sight, hearing and organ function. This approach can
therefore be effective in treating common conditions such as post-infarction heart failure, and
trials targeting a broad spectrum of new indications are underway. So far, three IL-1-targeted …
Abstract
Interleukin-1 (IL-1) is a highly active pro-inflammatory cytokine that lowers pain thresholds and damages tissues. Monotherapy blocking IL-1 activity in autoinflammatory syndromes results in a rapid and sustained reduction in disease severity, including reversal of inflammation-mediated loss of sight, hearing and organ function. This approach can therefore be effective in treating common conditions such as post-infarction heart failure, and trials targeting a broad spectrum of new indications are underway. So far, three IL-1-targeted agents have been approved: the IL-1 receptor antagonist anakinra, the soluble decoy receptor rilonacept and the neutralizing monoclonal anti-IL-1β antibody canakinumab. In addition, a monoclonal antibody directed against the IL-1 receptor and a neutralizing anti-IL-1α antibody are in clinical trials.
nature.com